Liver Cancer Treatment in Shanghai: What International Patients Need to Know

Liver cancer is one of the most common and serious cancers worldwide, ranking sixth in incidence and third in cancer-related mortality globally. For patients diagnosed with primary liver cancer — particularly hepatocellular carcinoma (HCC) — finding the right treatment center is one of the most consequential decisions they will make. Shanghai has emerged as a destination of genuine clinical significance for international patients, not simply because of cost, but because of the sheer volume of cases treated and the depth of specialist expertise concentrated in the city.

Understanding Liver Cancer: The Basics

Liver cancer broadly refers to malignancies that originate in the liver. The two most common types are:

• Hepatocellular Carcinoma (HCC): Accounts for approximately 75–85% of all primary liver cancers. It typically arises in the setting of chronic liver disease, most commonly hepatitis B or C infection, alcoholic cirrhosis, or non-alcoholic fatty liver disease (NAFLD). HCC is the dominant form of liver cancer in East Asia.
• Intrahepatic Cholangiocarcinoma (iCCA): A cancer of the bile ducts within the liver. Less common than HCC but often more challenging to treat due to late presentation and limited systemic therapy options historically.

Secondary liver cancer — where cancer from another organ (colon, breast, lung) spreads to the liver — is also common and may be treated with some of the same techniques, though the primary diagnosis drives the overall treatment strategy.

Staging: Why It Matters

Treatment decisions for liver cancer are heavily stage-dependent. The Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used framework internationally and is also applied in Shanghai's leading hospitals. It classifies HCC into five stages:

• Stage 0 (Very Early): Single tumor ≤2 cm, preserved liver function. Best candidates for curative resection or ablation.
• Stage A (Early): Single tumor or up to 3 nodules ≤3 cm. Eligible for resection, transplantation, or ablation.
• Stage B (Intermediate): Multinodular disease without vascular invasion or metastasis. TACE is the standard of care.
• Stage C (Advanced): Vascular invasion or extrahepatic spread. Systemic therapy (targeted agents, immunotherapy) is the primary approach.
• Stage D (Terminal): Severely impaired liver function. Palliative care is prioritized.

Accurate staging requires high-quality imaging — typically a contrast-enhanced CT scan or MRI with liver-specific contrast agents — and assessment of liver function using the Child-Pugh or MELD score.

Why Shanghai Has Exceptional Liver Cancer Expertise

China accounts for approximately 50% of all new liver cancer cases globally each year, largely driven by the high prevalence of hepatitis B. This epidemiological reality has made liver cancer a national clinical priority for decades. Shanghai's major hepatobiliary centers have accumulated case volumes that are simply unmatched in most parts of the world.

Zhongshan Hospital, affiliated with Fudan University, is consistently ranked among China's top hospitals for hepatobiliary surgery. Its liver cancer center performs over 3,000 liver surgeries annually. The Eastern Hepatobiliary Surgery Hospital (part of the Naval Medical University) is one of the largest dedicated liver cancer centers in the world, with a research output that has shaped international treatment guidelines. Renji Hospital and Ruijin Hospital also maintain strong hepatobiliary programs with active clinical trial participation.

Many senior surgeons at these institutions have trained internationally, hold dual appointments at research universities, and publish regularly in journals such as Hepatology, Journal of Hepatology, and Annals of Surgery.

Surgical Treatment: Liver Resection

Surgical resection — removing the tumor along with a margin of healthy liver tissue — remains the gold standard for early-stage HCC in patients with adequate liver function and sufficient residual liver volume. The liver's remarkable regenerative capacity means that up to 70% of the organ can be removed in suitable patients.

Shanghai surgeons are highly experienced in both open and laparoscopic (minimally invasive) hepatectomy. Laparoscopic resection, when feasible, offers significant advantages: smaller incisions, reduced blood loss, shorter hospital stays (typically 5–7 days versus 10–14 days for open surgery), and faster return to normal activity. Robotic-assisted hepatectomy is also available at select centers.

Five-year survival rates following curative resection for early-stage HCC at Shanghai's top centers range from 50–70%, comparable to or exceeding outcomes reported at leading Western institutions.

Liver Transplantation

For patients with early-stage HCC who also have significant underlying cirrhosis — making resection risky due to poor residual liver function — liver transplantation offers the dual benefit of removing the tumor and replacing the diseased liver. The Milan Criteria (single tumor ≤5 cm, or up to 3 tumors each ≤3 cm, no vascular invasion, no extrahepatic spread) are used internationally to identify transplant candidates with the best outcomes.

Liver transplantation in China is governed by strict national regulations. Organ allocation follows the China Liver Transplant Registry (CLTR) system. Foreign nationals considering transplantation in China should seek detailed, current legal and medical guidance, as eligibility and wait-time dynamics differ from Western systems.

Interventional Oncology: TACE, TARE, and Ablation

For patients who are not surgical candidates — due to tumor location, multifocal disease, or impaired liver function — a range of minimally invasive interventional procedures are available:

• Transarterial Chemoembolization (TACE): The most widely used locoregional therapy for intermediate-stage HCC. A catheter is threaded through the femoral artery to the hepatic artery supplying the tumor. Chemotherapy (typically doxorubicin or cisplatin) combined with an embolic agent is injected directly into the tumor's blood supply, simultaneously delivering high-dose chemotherapy and cutting off the tumor's oxygen supply. Drug-eluting bead TACE (DEB-TACE) is a refinement that provides more sustained drug release.
• Transarterial Radioembolization (TARE / SIRT): Similar catheter-based approach, but delivers radioactive microspheres (Yttrium-90) directly to the tumor. Particularly useful for tumors with portal vein involvement where conventional TACE may be contraindicated.
• Radiofrequency Ablation (RFA): A needle electrode is inserted into the tumor under ultrasound or CT guidance, delivering radiofrequency energy that heats and destroys tumor tissue. Most effective for tumors ≤3 cm. Can be performed percutaneously (through the skin), laparoscopically, or during open surgery.
• Microwave Ablation (MWA): Similar principle to RFA but uses microwave energy, which generates higher temperatures more rapidly and is less affected by the heat-sink effect of nearby blood vessels. Increasingly preferred over RFA for tumors near large vessels.
• Irreversible Electroporation (IRE / NanoKnife): A non-thermal ablation technique that uses electrical pulses to create permanent pores in cell membranes, causing cell death without heat. Particularly useful for tumors adjacent to bile ducts or major vessels where thermal ablation carries higher risk.

Systemic Therapy: Targeted Agents and Immunotherapy

The systemic treatment landscape for advanced HCC has transformed dramatically over the past decade. First-line options now include:

• Atezolizumab + Bevacizumab (Atezo/Bev): The IMbrave150 trial established this combination as the preferred first-line regimen for advanced HCC, demonstrating superior overall survival compared to sorafenib. Atezolizumab is a PD-L1 immune checkpoint inhibitor; bevacizumab targets VEGF to inhibit tumor angiogenesis.
• Tremelimumab + Durvalumab (STRIDE regimen): An alternative first-line immunotherapy combination approved based on the HIMALAYA trial data.
• Sorafenib: The first targeted therapy approved for HCC, a multi-kinase inhibitor. Still used in certain clinical contexts, particularly where immunotherapy is contraindicated.
• Lenvatinib: A VEGFR inhibitor that demonstrated non-inferiority to sorafenib in the REFLECT trial and is preferred by some oncologists due to its response rate profile.
• Second-line options include regorafenib, cabozantinib, and ramucirumab (for patients with AFP ≥400 ng/mL).

All of these agents are available at Shanghai's major oncology centers. Biomarker testing — including PD-L1 expression, AFP levels, and increasingly genomic profiling — is used to guide treatment selection.

Radiation Therapy

While the liver has historically been considered sensitive to radiation, advances in precision radiotherapy have expanded its role in liver cancer management:

• Stereotactic Body Radiotherapy (SBRT): Delivers high-dose, precisely targeted radiation in a small number of fractions (typically 3–5). Effective for small HCC tumors and as a bridge to transplantation.
• Proton Beam Therapy: Available at select centers in Shanghai. Protons deposit most of their energy at the tumor site (Bragg peak), sparing surrounding liver tissue — particularly valuable in patients with limited hepatic reserve.

Multidisciplinary Team (MDT) Review

At Shanghai's leading liver cancer centers, every complex case is reviewed by a Multidisciplinary Team (MDT) comprising hepatobiliary surgeons, interventional radiologists, medical oncologists, radiation oncologists, hepatologists, and pathologists. This collaborative model — now standard at top institutions globally — ensures that treatment decisions integrate all relevant specialties rather than being driven by a single physician's perspective.

MDT meetings typically occur weekly. Patients referred through a concierge service can often have their imaging and pathology reviewed at an MDT session before they travel, arriving in Shanghai with a preliminary treatment plan already in place.

What Medical Records Are Required

To facilitate a specialist consultation or MDT review, patients should prepare the following:

• Contrast-enhanced CT scan or MRI of the abdomen (ideally within the past 2–3 months, in DICOM format on a disc or via secure digital transfer)
• Pathology report from any prior biopsy
• Blood tests: AFP, liver function tests (ALT, AST, bilirubin, albumin, PT/INR), complete blood count, hepatitis B surface antigen and HBV DNA (if applicable), hepatitis C antibody
• Child-Pugh or MELD score documentation (if available from your hepatologist)
• Summary of all prior treatments: surgery, ablation, TACE, systemic therapy with dates and response assessments
• Current medication list including any anticoagulants or immunosuppressants

Cost Considerations

Treatment costs in Shanghai are substantially lower than in Western countries, even at the highest-tier hospitals. As a general reference:

• Specialist consultation: USD 150–400
• Contrast-enhanced MRI (liver protocol): USD 300–600
• TACE procedure: USD 3,000–8,000 per session
• Laparoscopic liver resection: USD 15,000–30,000 (including hospital stay)
• Open major hepatectomy: USD 20,000–40,000
• Systemic therapy (per cycle, drug costs vary): USD 1,500–5,000

These figures are indicative and vary based on hospital tier, surgeon seniority, tumor complexity, and length of stay. A detailed cost estimate can be provided once medical records have been reviewed.

Frequently Asked Questions

How is liver cancer diagnosed in Shanghai — do I need a biopsy?
For HCC specifically, a biopsy is often not required if imaging findings are characteristic and AFP is elevated. International guidelines (EASL, AASLD) allow non-invasive diagnosis of HCC ≥1 cm based on imaging alone in patients with cirrhosis. Shanghai radiologists are experienced in applying these criteria. For cholangiocarcinoma or uncertain diagnoses, tissue sampling is typically required.

What is the typical hospital stay for liver surgery?
Laparoscopic resection: 5–8 days. Open hepatectomy: 10–14 days. Patients are generally advised to remain in Shanghai for 2–4 weeks post-discharge before long-haul travel, depending on recovery progress.

Can I continue systemic therapy started in my home country?
In most cases, yes. Shanghai oncologists are familiar with international treatment protocols and can continue or modify regimens as appropriate. Bring documentation of your current regimen, dosing, and any adverse events.

Is hepatitis B treatment managed alongside liver cancer treatment?
Yes. Antiviral therapy for hepatitis B (typically tenofovir or entecavir) is routinely co-managed with liver cancer treatment to suppress viral replication and protect residual liver function.

Planning Your Treatment in Shanghai

If you or a family member has been diagnosed with liver cancer and would like to explore treatment options in Shanghai, China Medical Concierge (CMCS) can help coordinate your consultation, hospital placement, translation, and logistics. Contact us for a confidential initial review.